Osteopontin as a Tumor Marker in Ovarian Cancer.
J Midlife Health. 2022 Jul-Sep; 13(3):200-205.JM

Abstract

Introduction

Ovarian cancer is associated with high morbidity and mortality. This is due to the nonspecific symptoms and no effective screening methods. Currently, carbohydrate antigen-125 (CA125) is used as a tumor biomarker for the diagnosis of ovarian cancer, but it has its own limitations. Hence, there is a need for other tumor biomarkers for the diagnosis of ovarian cancer. Objective of the study was to evaluate the diagnostic test characteristics of plasma osteopontin (OPN) in detecting ovarian malignancy and comparing its performance with CA125.

Materials and Methods

This is a prospective cross-sectional diagnostic test evaluation. Women with adnexal mass detected by clinical or radiological examination were enrolled as suspected cases. Women who presented with other gynecological conditions were enrolled as controls. OPN and CA125 levels were measured in all enrolled subjects.

Results

Among 106 women enrolled, 26 were ovarian cancer, 31 had benign ovarian masses, and 49 were controls. Median plasma CA125 levels were higher in subjects with ovarian cancer (298 U/ml; interquartile range [IQR]: 84-1082 U/ml vs. 37.5U/ml; IQR: 17.6-82.9U/ml; P < 0.001). CA125 sensitivity, specificity, positive, and negative likelihood ratios were 88.5%, 61.3%, 2.10, and 0.19, respectively. Median plasma OPN levels were higher in subjects with ovarian cancer (63.1 ng/ml; IQR: 39.3-137 ng/ml vs. 27 ng/ml; IQR: 20-52 ng/ml; P = 0.001). Sensitivity, specificity, positive, and negative likelihood ratios of OPN were 50%, 87%, 2.58, and 0.62, respectively.

Conclusion

OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125.

Links

PMC Free PDF

Authors+Show Affiliations

Rani S

Department of Obstetrics and Gynaecology, Dr. BR Ambedkar Institute of Medical Sciences, Mohali, Punjab, India.

Sehgal A

Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Chandigarh, India.

Kaur J

Department of Biochemistry, Government Medical College and Hospital, Chandigarh, India.

Pandher DK

Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Chandigarh, India.

Punia RS

Department of Pathology, Government Medical College and Hospital, Chandigarh, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36950209

Citation

Rani, Shikha, et al. "Osteopontin as a Tumor Marker in Ovarian Cancer." Journal of Mid-life Health, vol. 13, no. 3, 2022, pp. 200-205.

Rani S, Sehgal A, Kaur J, et al. Osteopontin as a Tumor Marker in Ovarian Cancer. J Midlife Health. 2022;13(3):200-205.

Rani, S., Sehgal, A., Kaur, J., Pandher, D. K., & Punia, R. S. (2022). Osteopontin as a Tumor Marker in Ovarian Cancer. Journal of Mid-life Health, 13(3), 200-205. https://doi.org/10.4103/jmh.jmh_52_22

Rani S, et al. Osteopontin as a Tumor Marker in Ovarian Cancer. J Midlife Health. 2022 Jul-Sep;13(3):200-205. PubMed PMID: 36950209.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Osteopontin as a Tumor Marker in Ovarian Cancer. AU - Rani,Shikha, AU - Sehgal,Alka, AU - Kaur,Jasbinder, AU - Pandher,Dilpreet Kaur, AU - Punia,Rajpal Singh, Y1 - 2023/01/14/ PY - 2022/02/18/received PY - 2022/08/17/revised PY - 2022/08/18/accepted PY - 2023/3/23/entrez PY - 2023/3/24/pubmed PY - 2023/3/24/medline KW - Carbohydrate antigen-125 KW - osteopontin KW - ovarian cancer KW - tumor marker SP - 200 EP - 205 JF - Journal of mid-life health JO - J Midlife Health VL - 13 IS - 3 N2 - Introduction: Ovarian cancer is associated with high morbidity and mortality. This is due to the nonspecific symptoms and no effective screening methods. Currently, carbohydrate antigen-125 (CA125) is used as a tumor biomarker for the diagnosis of ovarian cancer, but it has its own limitations. Hence, there is a need for other tumor biomarkers for the diagnosis of ovarian cancer. Objective of the study was to evaluate the diagnostic test characteristics of plasma osteopontin (OPN) in detecting ovarian malignancy and comparing its performance with CA125. Materials and Methods: This is a prospective cross-sectional diagnostic test evaluation. Women with adnexal mass detected by clinical or radiological examination were enrolled as suspected cases. Women who presented with other gynecological conditions were enrolled as controls. OPN and CA125 levels were measured in all enrolled subjects. Results: Among 106 women enrolled, 26 were ovarian cancer, 31 had benign ovarian masses, and 49 were controls. Median plasma CA125 levels were higher in subjects with ovarian cancer (298 U/ml; interquartile range [IQR]: 84-1082 U/ml vs. 37.5U/ml; IQR: 17.6-82.9U/ml; P < 0.001). CA125 sensitivity, specificity, positive, and negative likelihood ratios were 88.5%, 61.3%, 2.10, and 0.19, respectively. Median plasma OPN levels were higher in subjects with ovarian cancer (63.1 ng/ml; IQR: 39.3-137 ng/ml vs. 27 ng/ml; IQR: 20-52 ng/ml; P = 0.001). Sensitivity, specificity, positive, and negative likelihood ratios of OPN were 50%, 87%, 2.58, and 0.62, respectively. Conclusion: OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125. SN - 0976-7800 UR - https://www.unboundmedicine.com/medline/citation/36950209/Osteopontin_as_a_Tumor_Marker_in_Ovarian_Cancer_ DB - PRIME DP - Unbound Medicine ER -

Tags

Osteopontin as a Tumor Marker in Ovarian Cancer.J Midlife Health. 2022 Jul-Sep; 13(3):200-205.JM